HTR2B: 5-hydroxytryptamine receptor 2B
G protein-coupled receptor for 5-hydroxytryptamine (serotonin).
- Drugs that act on it: 4
- Approved: 2
- In phases 1 to 3: 2
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on HTR2B, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Edison Therapeutics125%
- Novartis Pharmaceuticals125%
- Wyeth is now a wholly owned subsidiary of Pfizer125%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Serotonin 2b (5-HT2b) receptor antagonist; the rest name their own mechanism.| Methylergonovine | Approved | Edison Therapeutics | Small molecule | Partial agonistSerotonin 2b (5-HT2b) receptor partial agonist | 3 |
| Methysergide | Approved | Novartis Pharmaceuticals | Small molecule | Antagonist | 0 |
| PRX-08066 free base | Phase 2 | — | Small molecule | Antagonist | 0 |
| Vabicaserin | Phase 2 | Wyeth is now a wholly owned subsidiary of Pfizer | Small molecule | Antagonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR) | Methylergonovine | Phase 4 | Not yet recruiting | Stony Brook University | Jul 7, 2026 |
| Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy | Methylergonovine | Not applicable | Recruiting | Cairo University | Feb 5, 2026 |
| Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone | Methylergonovine | Not applicable | Not yet recruiting | Cairo University | Jan 6, 2026 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Schizophrenia
- 0.59
- Hemorrhage
- 0.59
- Post operative nausea and vomiting
- 0.48
- Psychotic disorder
- 0.48
- Obesity disorder
- 0.47
- Spontaneous abortion
- 0.37
- Drooling
- 0.26
- Bardet-Biedl syndrome
- 0.11
Genes and related targets
Complexes and families that share a gene with this target- Genes
- HTR2B
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1833, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P41595, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets